+++curr med chem and expert opin pharmacotheraphy

[gripin1984]

hi,
i need 2 srticle for my project pls,

JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
J. Trelinski and T. Robak
Current Medicinal Chemistry, 2013, 20, 9, 1147-1161

DOI:

http://dx.doi.org/10.2174/0929867311320090004

Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib
Kunihiro Yamaoka, Yoshiya Tanaka
Expert Opinion on Pharmacotherapy, 2014, 15, 1, 103-113

DOI:

http://dx.doi.org/10.1517/14656566.2014.854771

thanks

note: 1 more pls

Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012
Brian W Dymock, Cheng Shang See
Expert Opinion on Therapeutic Patents, April 2013, Vol. 23, No. 4 : Pages 449-501
DOI:

Код: Выделить всё

http://dx.doi.org/10.1517/13543776.2013.765862

[radfen]

1

[Ivan110]

0103.pdf

0449.pdf

[gripin1984]

hi,
i need 2 srticle for my project pls,

JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
J. Trelinski and T. Robak
Current Medicinal Chemistry, 2013, 20, 9, 1147-1161

DOI:

http://dx.doi.org/10.2174/0929867311320090004

Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib
Kunihiro Yamaoka, Yoshiya Tanaka
Expert Opinion on Pharmacotherapy, 2014, 15, 1, 103-113

DOI:

http://dx.doi.org/10.1517/14656566.2014.854771

thanks

note: 1 more pls

Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012
Brian W Dymock, Cheng Shang See
Expert Opinion on Therapeutic Patents, April 2013, Vol. 23, No. 4 : Pages 449-501
DOI:

Код: Выделить всё

http://dx.doi.org/10.1517/13543776.2013.765862